Esomeprazole

Generic Name
Esomeprazole
Brand Names
Nexium, Vimovo, Nexium Control
Drug Type
Small Molecule
Chemical Formula
C17H19N3O3S
CAS Number
119141-88-7
Unique Ingredient Identifier
N3PA6559FT
Background

Esomeprazole, sold under the brand name Nexium, is a proton pump inhibitor (PPI) medication used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome. It can also be found in quadruple regimens for the treatment of H. pylori infections along with other antibiotics including Amoxicillin, Clarithromycin, and Metronidazole, for example. Its efficacy is considered similar to other medications within the PPI class including Omeprazole, Pantoprazole, Lansoprazole, Dexlansoprazole, and Rabeprazole. Esomeprazole is the s-isomer of Omeprazole, which is a racemate of the S- and R-enantiomer. Esomeprazole has been shown to inhibit acid secretion to a similar extent as Omeprazole, without any significant differences between the two compounds in vitro.

Esomeprazole exerts its stomach acid-suppressing effects by preventing the final step in gastric acid production by covalently binding to sulfhydryl groups of cysteines found on the (H+, K+)-ATPase enzyme at the secretory surface of gastric parietal cells. This effect leads to inhibition of both basal and stimulated gastric acid secretion, irrespective of the stimulus. As the binding of esomeprazole to the (H+, K+)-ATPase enzyme is irreversible and new enzyme needs to be expressed in order to resume acid secretion, esomeprazole's duration of antisecretory effect persists longer than 24 hours.

PPIs such as esomeprazole have also been shown to inhibit the activity of dimethylarginine dimethylaminohydrolase (DDAH), an enzyme necessary for cardiovascular health. DDAH inhibition causes a consequent accumulation of the nitric oxide synthase inhibitor asymmetric dimethylarginie (ADMA), which is thought to cause the association of PPIs with increased risk of cardiovascular events in patients with unstable coronary syndromes.

Due to their good safety profile and as several PPIs are available over the counter without a prescription, their current use in North America is widespread. Long term use of PPIs such as esomeprazole has been associated with possible adverse effects, however, including increased susceptibility to bacterial infections (including gastrointestinal C. difficile), reduced absorption of micronutrients such as iron and B12, and an increased risk of developing hypomagnesemia and hypocalcemia which may contribute to osteoporosis and bone fractures later in life.

Rapid discontinuation of PPIs such as esomeprazole may cause a rebound effect and a short term increase in hypersecretion. Esomeprazole doses should be slowly lowered, or tapered, before discontinuing to prevent this rebound effect.

Indication

Esomeprazole is indicated for the treatment of acid-reflux disorders including healing and maintenance of erosive esophagitis, and symptomatic gastroesophageal reflux disease (GERD), peptic ulcer disease, H. pylori eradication, prevention of gastrointestinal bleeds with NSAID use, and for the long-term treatment of pathological hypersecretory conditions including Zollinger-Ellison Syndrome.

Associated Conditions
Duodenal Ulcer, Erosive Esophagitis, Gastro-esophageal Reflux Disease (GERD), Heartburn, Helicobacter Pylori Infection, Stress Ulcers, Upper Gastrointestinal Hemorrhage, Zollinger-Ellison Syndrome, Acute benign gastric ulcers, Develop NSAID-induced gastric ulcers, Maintenance of healing Erosive esophagitis, Postendoscopy Bleeding
Associated Therapies
-

Effect of Proton Pump Inhibitors on CF Pulmonary Exacerbations

Phase 2
Completed
Conditions
Interventions
First Posted Date
2013-11-14
Last Posted Date
2022-02-17
Lead Sponsor
Columbia University
Target Recruit Count
21
Registration Number
NCT01983774
Locations
🇺🇸

Columbia University Cystic Fibrosis Center, New York, New York, United States

The PK and PD Interaction Between YH4808, Amoxicillin and Clarithromycin in Healthy Subjects

First Posted Date
2013-08-13
Last Posted Date
2013-12-03
Lead Sponsor
Yuhan Corporation
Target Recruit Count
95
Registration Number
NCT01921647
Locations
🇰🇷

Yonsei University Severance Hospital, Seoul, Korea, Republic of

15-day Sequential Therapy for Helicobacter Pylori Infection in Korea

First Posted Date
2013-06-26
Last Posted Date
2013-08-13
Lead Sponsor
Seoul National University Bundang Hospital
Target Recruit Count
287
Registration Number
NCT01887249
Locations
🇰🇷

Seoul National University Bundang Hospital, Bundang-gu, Seongnam, Gyeonggi-do, Korea, Republic of

PPI for Prevention of Post-sphincterotomy Bleeding

Phase 3
Completed
Conditions
Interventions
First Posted Date
2013-06-07
Last Posted Date
2016-07-18
Lead Sponsor
The University of Hong Kong
Target Recruit Count
185
Registration Number
NCT01873079
Locations
🇨🇳

Queen Mary Hospital, Hong Kong, China

Benefit of Pharyngeal and Oesophageal pH-impedance of Patients With High Suspicion of Laryngopharyngeal Reflux

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2013-05-16
Last Posted Date
2015-07-23
Lead Sponsor
University Hospital, Bordeaux
Target Recruit Count
30
Registration Number
NCT01854970
Locations
🇫🇷

CHU de Bordeaux, Bordeaux, France

Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety

First Posted Date
2013-03-28
Last Posted Date
2013-03-28
Lead Sponsor
Il-Yang Pharm. Co., Ltd.
Target Recruit Count
40
Registration Number
NCT01820143
Locations
🇨🇦

MDS Pharma Services, Québec, Canada

Long-term Follow up Helicobacter Pylori Reinfection Rate After Second-Line Treatment: Bismuth-Containing Quadruple Therapy Versus Moxifloxacin-Based Triple Therapy

First Posted Date
2013-02-15
Last Posted Date
2013-02-15
Lead Sponsor
Seoul National University Bundang Hospital
Target Recruit Count
648
Registration Number
NCT01792700
Locations
🇰🇷

Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea, Republic of

Twenty-Four Hour Combined Multi-Channel Impedance and pH Ambulatory Monitoring: Impedance Reflux Episodes of Patients On and Off Proton Pump Inhibitor Therapy

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2012-10-19
Last Posted Date
2013-01-09
Lead Sponsor
Walter Reed National Military Medical Center
Target Recruit Count
41
Registration Number
NCT01710800

Efficiency Study of Clarithromycin and Bismuth-containing Quadruple Therapy to Treat H.Pylori

First Posted Date
2012-08-17
Last Posted Date
2013-06-04
Lead Sponsor
Shanghai Jiao Tong University School of Medicine
Target Recruit Count
180
Registration Number
NCT01667575
Locations
🇨🇳

Renji Hospital, Shanghai, Shanghai, China

© Copyright 2024. All Rights Reserved by MedPath